mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

Colorectal cancers (CRCs) harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug screen, we have developed a novel therapeutic strategy that combines targeting of the apoptotic machinery using the BCL-2 family inhibitor ABT-263 (navitocl...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Faber, Anthony C., Coffee, Erin M., Costa, Carlotta, Dastur, Anahita, Ebi, Hiromichi, Hata, Aaron N., Yeo, Alan T., Edelman, Elena J., Song, Youngchul, Tam, Ah Ting, Boisvert, Jessica L., Milano, Randy J., Roper, Jatin, Kodack, David P., Jain, Rakesh K., Corcoran, Ryan B., Rivera, Miguel N., Ramaswamy, Sridhar, Hung, Kenneth E., Benes, Cyril H., Engelman, Jeffrey A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2013
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3973435/
https://ncbi.nlm.nih.gov/pubmed/24163374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0315
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk